What one share of AbCellera Biologics holds
AbCellera is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. We have built a platform for advancing antibody drug programs that we believe provides us with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities including multispecifics and antibody-drug conjugates.
AbCellera Biologics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.22 |
|---|---|
| Profit | −$0.55 |
| Capex (buildings and equipment) | $0.08 |
| Free cash flow | −$0.40 |
| Cash and investments | $0.39 |
| Book value | $2.92 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$0.01 | $0.03 | −$0.01 | — | $0.07 |
| 2020 | $0.89 | $0.45 | $0.04 | $0.05 | — | $3.08 |
| 2021 | $1.18 | $0.48 | $0.18 | $0.58 | — | $3.62 |
| 2022 | $1.54 | $0.50 | $0.22 | $0.66 | — | $4.30 |
| 2023 | $0.13 | −$0.51 | $0.27 | −$0.42 | — | $3.96 |
| 2024 | $0.10 | −$0.55 | $0.27 | −$0.64 | — | $3.57 |
| 2025 | $0.25 | −$0.49 | $0.14 | −$0.58 | — | $3.22 |
Common questions about AbCellera Biologics
How much does one share of AbCellera Biologics earn?
Over the last 12 months, AbCellera Biologics lost $0.55 for each share on $0.22 of sales.
Does AbCellera Biologics pay a dividend?
AbCellera Biologics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is AbCellera Biologics’s book value per share?
AbCellera Biologics’s book value is $2.92 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of AbCellera Biologics have?
Each share of AbCellera Biologics has $0.39 of cash and investments, as of June 30, 2026.
What is AbCellera Biologics’s free cash flow per share?
−$0.40 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has AbCellera Biologics bought back shares?
AbCellera Biologics’s share count rose about 97% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.